These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10594691)

  • 1. Anterior chamber-associated immune deviation-inducing cells activate T cells, and rescue them from antigen-induced apoptosis.
    Takeuchi M; Alard P; Verbik D; Ksander B; Streilein JW
    Immunology; 1999 Dec; 98(4):576-83. PubMed ID: 10594691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.
    Kezuka T; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1803-11. PubMed ID: 10845601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen-presenting cells are targets of regulatory T cells similar to those that mediate anterior chamber-associated immune deviation.
    Yokoi H; Streilein JW
    Ocul Immunol Inflamm; 2004 Jun; 12(2):101-14. PubMed ID: 15512980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation.
    Takeuchi M; Kosiewicz MM; Alard P; Streilein JW
    Eur J Immunol; 1997 Jul; 27(7):1648-56. PubMed ID: 9247573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells.
    Takeuchi M; Alard P; Streilein JW
    J Immunol; 1998 Feb; 160(4):1589-97. PubMed ID: 9469414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of in vivo regulatory properties of T cells activated in vitro by TGFbeta2-treated antigen presenting cells.
    Kezuka T; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1410-21. PubMed ID: 10798657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of inflammatory cytokines in induction of anterior chamber-associated immune deviation.
    Okamoto S; Streilein JW
    Ocul Immunol Inflamm; 1998 Mar; 6(1):1-11. PubMed ID: 9798188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type.
    Hara Y; Okamoto S; Rouse B; Streilein JW
    J Immunol; 1993 Nov; 151(10):5162-71. PubMed ID: 8228216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel role for TGF-beta and IL-10 in the induction of immune privilege.
    D'Orazio TJ; Niederkorn JY
    J Immunol; 1998 Mar; 160(5):2089-98. PubMed ID: 9498745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of eye-derived tolerance does not depend on naturally occurring CD4+CD25+ T regulatory cells.
    Keino H; Takeuchi M; Kezuka T; Hattori T; Usui M; Taguchi O; Streilein JW; Stein-Streilein J
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1047-55. PubMed ID: 16505040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nature of antigen in the eye has a profound effect on the cytokine milieu and resultant immune response.
    D'Orazio TJ; Niederkorn JY
    Eur J Immunol; 1998 May; 28(5):1544-53. PubMed ID: 9603459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for multiple CD95-CD95 ligand interactions in anteriorchamber-associated immune deviation induced by soluble protein antigen.
    Kezuka T; Streilein JW
    Immunology; 2000 Mar; 99(3):451-7. PubMed ID: 10712676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using tolerance induced via the anterior chamber of the eye to inhibit Th2-dependent pulmonary pathology.
    Katagiri K; Zhang-Hoover J; Mo JS; Stein-Streilein J; Streilein JW
    J Immunol; 2002 Jul; 169(1):84-9. PubMed ID: 12077232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical contribution of CD80 and CD86 to induction of anterior chamber-associated immune deviation.
    Tsukahara R; Takeuchi M; Akiba H; Kezuka T; Takeda K; Usui Y; Usui M; Yagita H; Okumura K
    Int Immunol; 2005 May; 17(5):523-30. PubMed ID: 15778288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Th1 and Th2 cells in anterior chamber-associated immune deviation.
    Li XY; D'Orazio LT; Niederkorn JY
    Immunology; 1996 Sep; 89(1):34-40. PubMed ID: 8911137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1.
    D'Orazio TJ; Mayhew E; Niederkorn JY
    J Immunol; 2001 Jan; 166(1):26-32. PubMed ID: 11123273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T regulatory cells use a novel genetic program that includes CD103 to suppress Th1 immunity in eye-derived tolerance.
    Keino H; Masli S; Sasaki S; Streilein JW; Stein-Streilein J
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1533-42. PubMed ID: 16565389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of anterior chamber-associated immune deviation with lymphoreticular allogeneic cells.
    Okamoto S; Hara Y; Streilein JW
    Transplantation; 1995 Feb; 59(3):377-81. PubMed ID: 7871568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell immunity induced by allogeneic microglia in relation to neuronal retina transplantation.
    Ma N; Streilein JW
    J Immunol; 1999 Apr; 162(8):4482-9. PubMed ID: 10201985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-borne signals that induce anterior chamber-associated immune deviation after intracameral injection of antigen.
    Streilein JW; Okamoto S; Hara Y; Kosiewicz M; Ksander B
    Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2245-54. PubMed ID: 9344347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.